Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772]

Subjects

Subjects :

*HER2 positive breast cancer
*TRASTUZUMAB

Details

Language :

English

ISSN :

09237534

Volume :

33

Issue :

3

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

155152782

Full Text :

https://doi.org/10.1016/j.annonc.2021.12.008